{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:17:40Z","timestamp":1788351460781,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.carrev.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:40:31Z","timestamp":1786603231000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three-month versus twelve-month dual antiplatelet therapy after acute coronary syndrome: An updated meta-analysis of randomized trials with trial sequential analysis"],"prefix":"10.1016","author":[{"given":"Christopher","family":"Chinnatambi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rahaman","family":"Ottun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Sakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"Darko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baffour","family":"Otchere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Daaim","family":"Mohammed-Murtala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammudeen","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzoma","family":"Ibebuogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triston","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Mungee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.carrev.2026.08.004_bb0005","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.carrev.2026.08.004_bb0010","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.carrev.2026.08.004_bb0015","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"152","author":"Levine","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"9562","key":"10.1016\/j.carrev.2026.08.004_bb0020","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"issue":"9985","key":"10.1016\/j.carrev.2026.08.004_bb0025","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.carrev.2026.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.carrev.2026.08.004_bb0035","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9281","key":"10.1016\/j.carrev.2026.08.004_bb0040","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.carrev.2026.08.004_bb0045","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.carrev.2026.08.004_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.carrev.2026.08.004_bb0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.carrev.2026.08.004_bb0060","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehp275","article-title":"Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period","volume":"30","author":"Schulz","year":"2009","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.carrev.2026.08.004_bb0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.amjcard.2008.11.038","article-title":"Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation","volume":"103","author":"Roy","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.carrev.2026.08.004_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCINTERVENTIONS.109.919936","article-title":"Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix","volume":"3","author":"Granada","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.carrev.2026.08.004_bb0075","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4244\/EIJV7I8A155","article-title":"Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials","volume":"7","author":"Navarese","year":"2011","journal-title":"EuroIntervention"},{"issue":"26","key":"10.1016\/j.carrev.2026.08.004_bb0080","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/eurheartj\/ehy275","volume":"39","author":"Saito","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.carrev.2026.08.004_bb0085","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jcin.2009.10.006","article-title":"Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial","volume":"2","author":"Kim","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"issue":"10439","key":"10.1016\/j.carrev.2026.08.004_bb0090","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2026.08.004_bb0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2017.06.022","article-title":"Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials","volume":"244","author":"De Luca","year":"2017","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.carrev.2026.08.004_bb0100","doi-asserted-by":"crossref","first-page":"1325.e1","DOI":"10.1016\/j.amjmed.2017.05.029","article-title":"Duration of dual antiplatelet therapy in patients with an acute coronary syndrome undergoing percutaneous coronary intervention","volume":"130","author":"Bavishi","year":"2017","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.carrev.2026.08.004_bb0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurheartj\/ehaa739","volume":"42","author":"Giacoppo","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.carrev.2026.08.004_bb0110","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamacardio.2024.3216","article-title":"Short-term dual antiplatelet therapy after drug-eluting stenting in patients with acute coronary syndromes: a systematic review and network meta-analysis","volume":"9","author":"Carvalho","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.carrev.2026.08.004_bb0115","first-page":"1151","article-title":"Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials","volume":"100","author":"Selvaraj","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2026.08.004_bb0120","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.carrev.2026.08.004_bb0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1017\/S0266462300102181","article-title":"A study of the references used in Cochrane protocols and reviews. Three bibles, three dictionaries, and nearly 25,000 other things","volume":"16","author":"Clarke","year":"2000","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.carrev.2026.08.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-018-0699-4","article-title":"Registration of systematic reviews in PROSPERO: 30,000 records and counting","volume":"7","author":"Page","year":"2018","journal-title":"Syst Rev"},{"key":"10.1016\/j.carrev.2026.08.004_bb0135","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.carrev.2026.08.004_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074495","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.carrev.2026.08.004_bb0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"11","key":"10.1016\/j.carrev.2026.08.004_bb0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.carrev.2026.08.004_bb0155","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.carrev.2026.08.004_bb0160","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1177\/0962280215583568","article-title":"Random-effects meta-analysis: the number of studies matters","volume":"26","author":"Guolo","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.carrev.2026.08.004_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-018-0618-3","article-title":"Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies","volume":"19","author":"Seide","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.carrev.2026.08.004_bb0170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review","volume":"78","author":"Pocock","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.carrev.2026.08.004_bb0175","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"23","key":"10.1016\/j.carrev.2026.08.004_bb0180","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.carrev.2026.08.004_bb0185","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.carrev.2026.08.004_bb0190","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0877","article-title":"P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after deployment of a drug-eluting stent: the SHARE randomized clinical trial","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.carrev.2026.08.004_bb0195","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"37","key":"10.1016\/j.carrev.2026.08.004_bb0200","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","article-title":"Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS","volume":"41","author":"Baber","year":"2020","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.carrev.2026.08.004_bb0210","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.carrev.2026.08.004_bb0215","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-discharge bleeding and mortality following acute coronary syndromes with or without PCI","volume":"76","author":"Marquis-Gravel","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.carrev.2026.08.004_bb0220","doi-asserted-by":"crossref","first-page":"54","DOI":"10.15420\/ecr.2018:8:2","article-title":"The newest generation of drug-eluting stents and beyond","volume":"13","author":"Lee","year":"2018","journal-title":"Eur Cardiol"},{"issue":"7","key":"10.1016\/j.carrev.2026.08.004_bb0225","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacc.2015.11.051","article-title":"Safety and efficacy of everolimus- versus sirolimus-eluting stents","volume":"67","author":"Jensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.carrev.2026.08.004_bb0230","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.carrev.2026.08.004_bb0235","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.carrev.2026.08.004_bb0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.003519","article-title":"Postdischarge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction: insights from the HMO research network-stent registry","volume":"9","author":"Valle","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.carrev.2026.08.004_bb0245","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031606","article-title":"Review of the ticagrelor trials evidence base","volume":"13","author":"Herron","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"10.1016\/j.carrev.2026.08.004_bb0250","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jcin.2025.05.044","article-title":"Aspirin or P2Y12 inhibitor monotherapy after percutaneous coronary intervention for acute coronary syndromes","volume":"18","author":"Laudani","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.carrev.2026.08.004_bb0255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926003398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838926003398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:37:20Z","timestamp":1788349040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838926003398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S1553838926003398"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2026.08.004","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-month versus twelve-month dual antiplatelet therapy after acute coronary syndrome: An updated meta-analysis of randomized trials with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}